#ASH24: Early data on BTK degraders suggest promise of next-gen approachnews2024-12-10T20:44:46+00:00December 10th, 2024|Endpoints News|
NewAmsterdam hits primary endpoint in CETP inhibitor trialnews2024-12-10T19:52:53+00:00December 10th, 2024|Endpoints News|
Cases of severe RSV in two Moderna vaccine candidates’ trials raise questions about futurenews2024-12-10T17:24:12+00:00December 10th, 2024|Endpoints News|
Cardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offeringnews2024-12-10T16:02:35+00:00December 10th, 2024|Endpoints News|
Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trialnews2024-12-10T15:34:27+00:00December 10th, 2024|Endpoints News|
#SABCS24: Early data suggest Arvinas, Pfizer could combine their breast cancer drug with Lilly’s Verzenionews2024-12-10T15:08:42+00:00December 10th, 2024|Endpoints News|
BioNTech reports Phase 1b/2 survival data for VEGF bispecific in breast cancernews2024-12-10T14:00:11+00:00December 10th, 2024|Endpoints News|
#SABCS24: Olema makes case for its oral SERD with fresh data cut from Phase 1b/2 breast cancer trialnews2024-12-10T12:00:33+00:00December 10th, 2024|Endpoints News|
#ASH24: BTK drugs from AstraZeneca, Lilly and BeiGene take center stage in CLLnews2024-12-10T02:59:46+00:00December 10th, 2024|Endpoints News|
#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myelomanews2024-12-10T02:28:02+00:00December 10th, 2024|Endpoints News|
